CN
EN

CN
EN

Excellence
Tenacious
Relentless

Media Release

Jan 02, 2024

YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024

YolTech invites partners, investors, and stakeholders to join the session

Share

Last

Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
Next

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

LATESTNEWS

CDE Clears IND Application for Therapeutic Candidate Targeting ATTR

Mar 18, 2024
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024

Mar 13, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA

Mar 04, 2024